Treatment-Resistant Depression
First patient dosed in study of synthetic psychedelic for treatment-resistant depression
Beckley Psytech announced dosing of the first patient in a phase 2b clinical trial of BPL-003, an intranasal synthetic formulation of the psychedelic compound 5-MeO-DMT for treatment-resistant depression.
Biomarker tracks depression recovery after deep brain stimulation
A small study of patients with treatment-resistant depression identified a brain-based biomarker of recovery following deep brain stimulation of the subcallosal cingulate.
Deep brain stimulation may provide long-term benefits in treatment-resistant depression
Subcallosal cingulate gyrus deep brain stimulation was generally safe and significantly improved depressive symptoms in patients with treatment-resistant depression, with results sustained up to 7 years, according to research.
Deep TMS improves quality of life in treatment-resistant depression
SAN FRANCISCO — For patients with treatment-resistant major depressive disorder, deep transcranial magnetic stimulation significantly improved symptoms and quality of life compared with sham, according to a poster presented here.
First dose administered in phase 2a psychedelic study for treatment-resistant depression
The first patient with treatment-resistant depression has received a dose of a novel intranasal psychedelic in a phase 2a trial, according to a press release from its manufacturer.
Antidepressant augmentation improved well-being compared with switch in adults with TRD
In older adults with treatment-resistant depression, antidepressant augmentation improved well-being significantly over 10 weeks compared with switching medications and was associated with higher incidence of remission.
Symptom remission with IV ketamine quicker than intranasal esketamine in TRD
For individuals diagnosed with treatment-resistant depression, response and remission rates for IV ketamine and intranasal esketamine were similar, but remission time was quicker with the former compared with the latter.
Repetitive transcranial magnetic stimulation effective in major depression
Repetitive transcranial magnetic stimulation was effective in routine treatment of medication-resistant major depression, according to findings published in the Journal of Affective Disorders.
Intervention key for major depressive disorder to prevent treatment-resistant depression
For those with major depressive disorder, early intervention is crucial to address treatment-resistant depression, which may lead to higher disease burden on the patient and health care system, per a study published in JAMA Psychiatry.
Phase 2a study initiated to examine synthetic DMT for treatment-resistant depression
A biotech company based in the U.K. announced that it has initiated a phase 2a study for BPL-003for treatment-resistant depression.